Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01783509 · ClinicalTrials.gov registry record
Limb Girdle Muscular Dystrophy (LGMD) Natural History
A clinical trial of Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED), sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT01783509 is a study of Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED) that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01783509, a study of Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED), has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand more about limb-girdle muscular dystrophy. Therefore, the investigators would like to track the following information collected once a year from patients with GENETICALLY CONFIRMED LGMD: quality of life questionnaires, muscle strength, motor function, routine examination, assessment of patient (or parent) understanding of LGMD, and serum (blood) for growth factors, cytokines, and biomarkers (all parts of your blood). By tracking this information, we hope to be able to understand more about the diagnosis, progression and natural history of this disorder.
Conditions Studied
Study Locations (1)
North Carolina
- Carolinas Medical Center - Pediatrics - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-11 |
| Est. Completion | 2017-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01783509
The ClinicalTrials.gov registry entry for NCT01783509 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED) appearing as the primary indexed condition, and to 0 interventions.
NCT01783509 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01783509 about?
NCT01783509 is a clinical study titled "Limb Girdle Muscular Dystrophy (LGMD) Natural History". The purpose of this study is to understand more about limb-girdle muscular dystrophy. Therefore, the investigators would like to track the following information collected once a year from patients with GENETICALLY CONFIRMED LGMD: quality of life questionnaires, muscle strength, motor function, routi...
What is the current status of trial NCT01783509?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2011-11. Estimated completion is 2017-07.
What conditions does trial NCT01783509 study?
This clinical trial studies the following conditions: Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED).
Who is sponsoring clinical trial NCT01783509?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01783509 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.